• Medientyp: E-Artikel
  • Titel: SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022
  • Beteiligte: Engels, Geraldine; Oechsle, Anna-Lisa; Schlegtendal, Anne; Maier, Christoph; Holzwarth, Sarah; Streng, Andrea; Lange, Berit; Karch, Andre; Petersmann, Astrid; Streeck, Hendrik; Blaschke-Steinbrecher, Sabine; Härtel, Christoph; Schroten, Horst; von Kries, Rüdiger; Berner, Reinhard; Liese, Johannes; Brinkmann, Folke; Toepfner, Nicole; Forster, Johannes; Kurzai, Oliver; Pietsch, Franziska; Hick, Elena; Hecker, Katharina; Lücke, Thomas; [...]
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: Infection
  • Sprache: Englisch
  • DOI: 10.1007/s15010-023-02052-5
  • ISSN: 0300-8126; 1439-0973
  • Schlagwörter: Infectious Diseases ; Microbiology (medical) ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>The study evaluates the effects on sero-immunity, health status and quality of life of children and adolescents after the upsurge of the Omicron variant in Germany.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>This multicenter cross-sectional study (IMMUNEBRIDGE Kids) was conducted within the German Network University Medicine (NUM) from July to October 2022. SARS-CoV-2- antibodies were measured and data on SARS-CoV-2 infections, vaccinations, health and socioeconomic factors as well as caregiver-reported evaluation on their children’s health and psychological status were assessed.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>497 children aged 2–17 years were included. Three groups were analyzed: 183 pre-schoolchildren aged 2–4 years, 176 schoolchildren aged 5–11 years and 138 adolescents aged 12–18 years. Positive antibodies against the S- or N-antigen of SARS-CoV-2 were detected in 86.5% of all participants (70.0% [128/183] of pre-schoolchildren, 94.3% of schoolchildren [166/176] and 98.6% of adolescents [136/138]). Among all children, 40.4% (201/497) were vaccinated against COVID-19 (pre-schoolchildren 4.4% [8/183], schoolchildren 44.3% [78/176] and adolescents 83.3% [115/138]). SARS-CoV-2 seroprevalence was lowest in pre-school. Health status and quality of life reported by the parents were very positive at the time of the survey (Summer 2022).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Age-related differences on SARS-CoV-2 sero-immunity could mainly be explained by differences in vaccination rates based on the official German vaccination recommendations as well as differences in SARS-CoV-2 infection rates in the different age groups. Health status and quality of life of almost all children were very good independent of SARS-CoV-2 infection and/or vaccination.</jats:p> </jats:sec><jats:sec> <jats:title>Trial registration</jats:title> <jats:p>German Registry for Clinical Trials Identifier Würzburg: DRKS00025546 (registration: 11.09.2021), Bochum: DRKS00022434 (registration:07.08.2020), Dresden: DRKS 00022455 (registration: 23.07.2020).</jats:p> </jats:sec>